Company intelligence / Profile preview

Tonghua Anrate Biopharmaceutical

Tonghua, Jilin, China

Ownership: Private
Development stage: Other

Overview

Tonghua Anrate Biopharmaceutical’s recombinant human albumin injection has completed preclinical safety/toxicity studies, Phase Ia/Ib trials, Phase II, and begun Phase III clinical trials to evaluate safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics for patients with liver cirrhosis and ascites. Production license and GMP certification obtained.

Therapeutic areas: HematologyGastroenterology
Modalities: Recombinant protein
Industry: Biotech

Partnerships

Shanghai Anrate Biopharmaceutical Technology Co., Ltd.hospitals including First Hospital of Jilin University (clinical trial site)

Beyond the preview

Go deeper on Tonghua Anrate Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tonghua Anrate Biopharmaceutical.

Explore the full profile